Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis

S Gudbrandsdottir; H Bliddal; A Petri; L Terslev; B Danneskiold-Samsoe; B Bjørnhart; K Bendtzen; K Müller; Bente Danneskiold-Samsøe

Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis

S Gudbrandsdottir, H Bliddal, A Petri, L Terslev, B Danneskiold-Samsoe, B Bjørnhart, K Bendtzen, K Müller, Bente Danneskiold-Samsøe

11 Citations (Scopus)

Abstract

Etanercept (Enbrel) induces a rapid and sustained decline in disease activity in the majority of patients with refractory rheumatoid arthritis (RA). In these patients neutralization of TNFalpha and lymphotoxin (LT), previously termed TNFbeta is mediated by etanercept itself, as well as by naturally occurring soluble TNF receptors. However, the clinical response to treatment with etanercept may vary. Previously, pharmacokinetic studies have focused on the molar concentrations of etanercept, but very little is known about the kinetics of bioactive etanercept in patients treated with etanercept. The purpose of this study was to evaluate kinetics, including inter- and intraindividual variations of the total TNF binding capacity, in RA patients who were on a standard treatment schedule with etanercept.

Original language	English
Journal	Scandinavian Journal of Rheumatology
Volume	33
Issue number	6
Pages (from-to)	385-8
Number of pages	4
ISSN	0300-9742
Publication status	Published - 1 Jan 2004

Cite this

Gudbrandsdottir, S., Bliddal, H., Petri, A., Terslev, L., Danneskiold-Samsoe, B., Bjørnhart, B., Bendtzen, K., Müller, K., & Danneskiold-Samsøe, B. (2004). Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 33(6), 385-8.

@article{a3a2517aa5884c86ae6d5476f1407390,

title = "Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis",

abstract = "Etanercept (Enbrel) induces a rapid and sustained decline in disease activity in the majority of patients with refractory rheumatoid arthritis (RA). In these patients neutralization of TNFalpha and lymphotoxin (LT), previously termed TNFbeta is mediated by etanercept itself, as well as by naturally occurring soluble TNF receptors. However, the clinical response to treatment with etanercept may vary. Previously, pharmacokinetic studies have focused on the molar concentrations of etanercept, but very little is known about the kinetics of bioactive etanercept in patients treated with etanercept. The purpose of this study was to evaluate kinetics, including inter- and intraindividual variations of the total TNF binding capacity, in RA patients who were on a standard treatment schedule with etanercept.",

author = "S Gudbrandsdottir and H Bliddal and A Petri and L Terslev and B Danneskiold-Samsoe and B Bj{\o}rnhart and K Bendtzen and K M{\"u}ller and Bente Danneskiold-Sams{\o}e",

year = "2004",

month = jan,

day = "1",

language = "English",

volume = "33",

pages = "385--8",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis

AU - Gudbrandsdottir, S

AU - Bliddal, H

AU - Petri, A

AU - Terslev, L

AU - Danneskiold-Samsoe, B

AU - Bjørnhart, B

AU - Bendtzen, K

AU - Müller, K

AU - Danneskiold-Samsøe, Bente

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Etanercept (Enbrel) induces a rapid and sustained decline in disease activity in the majority of patients with refractory rheumatoid arthritis (RA). In these patients neutralization of TNFalpha and lymphotoxin (LT), previously termed TNFbeta is mediated by etanercept itself, as well as by naturally occurring soluble TNF receptors. However, the clinical response to treatment with etanercept may vary. Previously, pharmacokinetic studies have focused on the molar concentrations of etanercept, but very little is known about the kinetics of bioactive etanercept in patients treated with etanercept. The purpose of this study was to evaluate kinetics, including inter- and intraindividual variations of the total TNF binding capacity, in RA patients who were on a standard treatment schedule with etanercept.

AB - Etanercept (Enbrel) induces a rapid and sustained decline in disease activity in the majority of patients with refractory rheumatoid arthritis (RA). In these patients neutralization of TNFalpha and lymphotoxin (LT), previously termed TNFbeta is mediated by etanercept itself, as well as by naturally occurring soluble TNF receptors. However, the clinical response to treatment with etanercept may vary. Previously, pharmacokinetic studies have focused on the molar concentrations of etanercept, but very little is known about the kinetics of bioactive etanercept in patients treated with etanercept. The purpose of this study was to evaluate kinetics, including inter- and intraindividual variations of the total TNF binding capacity, in RA patients who were on a standard treatment schedule with etanercept.

M3 - Journal article

SN - 0300-9742

VL - 33

SP - 385

EP - 388

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - 6

ER -

Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis

Abstract

Fingerprint

Cite this